Membranous Nephropathy Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Membranous Nephropathy remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 173 matched trial records and 120 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| CTR20262538 | QLS7305 | Phase 2; 进行中 （尚未招募） | Qilu Pharmaceutical Co., Ltd. | China | (第12周、24周) | Timing not listed |
| NCT07614191 | GT801 | Early Phase 1; Recruiting | Vivacta Biotechnology (Shanghai) Co., Ltd. | China | Proportion of participants experiencing dose limiting toxicity (28 days); Adverse Events (AEs) occurring after infusion and their proportions (3 months) | 2031-12-30 |
| ChiCTR2600125299 | Mycophenolate Mofetil | Phase 4; Recruiting | Shanghai Huashan Hospital | China | overall remission rate | 2028-12-31 |
| CTR20261737 | FKC289 | Phase 1; 进行中 （尚未招募） | Fosun Kite Biotechnology Co., Ltd. | China | (28); (NA) | Timing not listed |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy (Phase 3): the indexed record reports CR(week 104) = 6.0 %; CR(week 104) = 37.0 %.
- Efficacy and Safety of FKC289, a BCMA-CD19 dual-targeted CAR-T therapy for refractory or relapsed PLA2R-associated Membranous Nephropathy (Phase 1): the indexed record reports DLT = due to prolonged liver toxicity.
- Membranous Nephropathy Meets a Novel Anti-CD19 & Anti-BCMA Dual CAR-T Therapy that’s a First in Human Clinical Performance and Manufactured Using an Innovative Fosunova T Platform (Phase 1): the indexed record reports eGFR(from baseline) = significantly increased %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including QLS7305 (Phase 2), GT801 (Early Phase 1; CD19), Mycophenolate Mofetil (Approved; IMPDH), FKC289 (Phase 1; BCMA x CD19). Company & Deal Intelligence records identify sponsor context for Qilu Pharmaceutical Co., Ltd., Vivacta Biotechnology (Shanghai) Co., Ltd., Shanghai Huashan Hospital, Fosun Kite Biotechnology Co., Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Membranous Nephropathy has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
